Cyclin D1 (CCND1) genotype is associated with tumour grade in sporadic pituitary adenomas.
The cyclin D1 (CCND1) gene contains a frequent A/G polymorphism within the splice donor region of exon 4/intron 4. CCND1 genotype is associated with clinical outcome in a number of malignancies although prognostic significance varies with tumour type. We examined CCND1 allele frequencies and genotype distribution in 294 patients with sporadic pituitary adenomas of various histologies. CCND1 allele frequencies and distribution of genotypes were similar in the 294 cases compared with previously reported control populations. Analysis according to tumour subtype showed no statistical difference in allele frequencies compared with controls. However, CCND1 genotype distribution in the somatotrophinomas showed a significant difference compared with normal controls (P = 0.008). We next examined CCND1 allele frequencies and genotype distribution across the tumour grades. Within the total tumour cohort the CCND1 allele frequencies showed a significant inverse relationship across the tumour grades (P = 0.005). The CCND1 A allele progressively increased from grade 1 (0.37) through to grade 4 (0.62) tumours, whilst the CCND1 G allele frequency progressively decreased from grade 1 (0.63) through to grade 4 (0.38) tumours. Trend analysis of CCND1 genotypes showed a significant progressive increase in AA frequency from grade 1 (15%) through to grade 4 (46%) tumours (P = 0.005). The CCND1 GG genotype progressively decreased from grade 1 (41%) through to grade 4 (23%) tumours (P = 0.204). No statistical significance was observed between CCND1 AG genotype and tumour grades. While the functional significance of the observed segregation of the CCND1 A/G polymorphism and tumour grade is unclear, our data suggest that CCND1 allele frequencies and genotype distributions show significant differences between tumour grades in sporadic pituitary adenomas. Since CCND1 genotype may be determined by analysis of peripheral blood samples it may provide a useful predictive marker for those tumours likely to show invasive behaviour. This may be clinically useful in indicating which tumours should receive adjunctive treatment (e.g. radiotherapy) immediately after surgical resection.
Simpson
D J
DJ
Centre for Cell and Molecular Medicine, School of Postgraduate Medicine, Keele University, North Staffordshire Hospital, Stoke-on-Trent ST4 7QB, UK.
Fryer
A A
AA
Grossman
A B
AB
Wass
J A
JA
Pfeifer
M
M
Kros
J M
JM
Clayton
R N
RN
Farrell
W E
WE
D000236:Adenoma / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D000324:Adrenocorticotropic Hormone / Q000235:genetics / Q000378:metabolism; D003062:Codon; D015331:Cohort Studies; D019938:Cyclin D1 / Q000235:genetics* / Q000378:metabolism; D017931:DNA Primers; D005091:Exons; D005838:Genotype; D013006:Growth Hormone / Q000235:genetics / Q000378:metabolism; D006801:Humans; D007438:Introns; D009367:Neoplasm Staging; D010911:Pituitary Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D015175:Prolactinoma / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D012008:Recurrence; D012189:Retrospective Studies; D017422:Sequence Analysis, DNA
D003062:Codon; D017931:DNA Primers; D019938:Cyclin D1; D000324:Adrenocorticotropic Hormone; D013006:Growth Hormone